{"id":"NCT04205643","sponsor":"Celltrion","briefTitle":"CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)","officialTitle":"A Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-01","primaryCompletion":"2022-07-07","completion":"2023-07-11","firstPosted":"2019-12-19","resultsPosted":"2023-09-28","lastUpdate":"2023-09-28"},"enrollment":548,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P13 SC (Infliximab)","otherNames":[]},{"type":"OTHER","name":"Placebo SC","otherNames":[]}],"arms":[{"label":"CT-P13 SC","type":"EXPERIMENTAL"},{"label":"Placebo SC","type":"PLACEBO_COMPARATOR"}],"summary":"This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Ulcerative Colitis","primaryOutcome":{"measure":"Percentage of Patients Achieving Clinical Remission at Week 54","timeFrame":"Week 54","effectByArm":[{"arm":"CT-P13 SC 120 mg","deltaMin":127,"sd":null},{"arm":"Placebo","deltaMin":30,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Poland"]},"refs":{"pmids":["40243842","38788861"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":548},"commonTop":["Headache","Anaemia","COVID-19","Colitis ulcerative","Nasopharyngitis"]}}